RIVKIN Aesthetics reports the rise of weight loss drugs like GLP-1 is reshaping aesthetics, with many new patients seeking ...

Relay Therapeutics is approaching a pivotal clinical catalyst with the zovegalisib Phase 1/2 data readout at ESMO TAT. Check out why RLAY stock is a buy.

Teresa Ghilarducci told Fortune that Trump is a “quirky, bold leader," but admits that if she was younger, she'd have ...

Research led by Penn Dental's Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as ...

The Energy Department has loaned $26.5 billion — the most in its history — to help a big Southeastern utility reduce the cost of building new power plants in Georgia and Alabama. Meanwhile, the nation ...

MUSC Health leadership voted this week to move ahead with a $111 million acquisition that would bring South Carolina’s largest independent multispecialty care practice under the academic system’s w | ...

Researchers at Kobe University have created an artificial intelligence system that can identify a rare endocrine disease simply by examining photos of ...

Dr. Carolyn Mukai, ND, Dr. Lynn Klassen, ND, Dr. Ece Toprak, ND Expanding recognition of infection-triggered ...

In sum, the nonapeptide Oxytocin presents as a structurally well-defined peptide with a receptor system that is widely distributed, ...

People on GLP-1s had slightly higher risks of osteoporosis and gout than similar people not taking these drugs. But diet and ...

Dr. Todd Maderis, ND  Exploring immune dysregulation, viral reactivation, mitochondrial impairment, and treatment implications in post-EBV fatigue syndromes ...